Position in NGNE
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$987,308
+$315,995 QoQ
Shares Held
31,393
-30.1% QoQ
Ownership
0.157%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#42
of 111 holders
Holding Since
Sep 2024
5 quarters on record
Voting authority
Sole 0%
Shared 70%
None 30%
Common Shares in NGNE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026WELLINGTON MANAGEMENT GROUP LLP holds $14,994,233,945 across 206 Biotechnology names. NGNE ranks #160 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
3,247,658 | $1,613,209,155 | |
| 2 | ARGX |
Argenx SE
|
930,548 | $863,334,513 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,270,087 | $791,950,042 | |
| 4 | RVMD |
Revolution Medicines, Inc.
|
3,843,415 | $719,794,757 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
2,110,407 | $635,295,816 | |
| 6 | IONS |
Ionis Pharmaceuticals Inc
|
7,651,415 | $606,680,693 | |
| 7 | CYTK |
Cytokinetics Inc
|
6,931,770 | $590,517,483 | |
| 8 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
825,714 | $443,367,129 |
All Filings in NGNE
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $987,308 | 31,393 | Shares | Defined | 2026-08-14 | |
| 2025-06-30 | $671,313 | 44,904 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $403,069 | 34,421 | Shares | Defined | 2025-05-13 | |
| 2024-12-31 | $496,450 | 21,717 | Shares | Defined | 2025-02-12 | |
| 2024-09-30 | $767,447 | 18,290 | Shares | Defined | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||